Once Daily Dosing for Kidney Transplant
(OnceDaily Trial)

Recruiting in Palo Alto (17 mi)

+2 other locations

Overseen byJohn Gill, MD

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of British Columbia

No Placebo Group

Trial Summary

What is the purpose of this trial?Patient failure to take medications as prescribed (medication non-adherence) is now identified as an important cause of kidney transplant failure. The availability of new drugs that are taken once daily may improve patient adherence compared to older drugs that had to be taken twice per day. In this study, patients will be converted to a medication schedule where all medications are taken once daily with the goal of improving patient adherence and satisfaction.

Eligibility Criteria

This trial is for kidney transplant recipients aged 12 and older who are at least one year post-transplantation, on specific immunosuppressants, and considered low risk. It's not for those with high antibody levels, unstable graft function, active infections or malignancies, or a history of non-adherence.

Inclusion Criteria

People who are at least 12 years old and adults who are at least 18 years old.

You are taking medications like tacrolimus, cyclosporin, or Advagraf.

You have only had one transplant and are considered low risk by the main doctor before being asked to join the study.

+5 more

Exclusion Criteria

You have had treatment to reduce your body's reaction to certain proteins or blood type differences in the past.

Your Panel Reactive Antibody (PRA) level is 30% or higher before the transplantation.

Unable to provide informed consent

+8 more

Participant Groups

The study tests if switching patients to once-daily medication regimens improves adherence and satisfaction. This includes converting to Advagraf (a once-daily immunosuppressant) and adjusting other meds to a single daily dose.

1Treatment groups

Experimental Treatment

Group I: Conversion to once daily dosingExperimental Treatment3 Interventions

The conversion to a once daily dosing regimen will be accomplished in three phases (1-conversion to Advagraf; 2-conversion of non-immunosuppressant drugs and; 3-conversion of patients taking twice daily MPA to once daily MPA). No control group.